acute axon injury and neurological deficits. The mechanisms of these correlations are unknown. We interrogated CTL-mediated axon injury using the transgenic OT-I antigen-specific CTL model system in conjunction with a chambered cortical neuron culture platform that permitted the isolated manipulation of axons independent of neuron cell bodies and glia. Interferon gamma upregulated, through a dose dependent mechanism, the axonal expression of functional major histocompatibility complex class I (MHC I) molecules competent to present immunologically-relevant antigens derived from endogenously expressed proteins. Antigen-specific CTLs formed cytotoxic immune synapses with and directly injured axons expressing antigen-loaded MHC I molecules. CTL-mediated axon injury was mechanistically dependent upon axonal MHC I antigen presentation, T cell receptor specificity and axoplasmic granzyme B activity. Despite extensive distal CTL-mediated axon injury, acute neuron cell body apoptosis was not observed. These findings present a novel model of immune-mediated axon injury and offer anti-axonal CTLs and granzyme B as targets for the therapeutic protection of axons and prevention of neurological deficits in MS patients.
Axon injury is a central determinant of irreversible neurological deficit and disease progression in patients with multiple sclerosis (MS). CD8 + lymphocytes (CTLs) within inflammatory demyelinated MS lesions correlate with acute axon injury and neurological deficits. The mechanisms of these correlations are unknown. We interrogated CTL-mediated axon injury using the transgenic OT-I antigen-specific CTL model system in conjunction with a chambered cortical neuron culture platform that permitted the isolated manipulation of axons independent of neuron cell bodies and glia. Interferon gamma upregulated, through a dose dependent mechanism, the axonal expression of functional major histocompatibility complex class I (MHC I) molecules competent to present immunologically-relevant antigens derived from endogenously expressed proteins. Antigen-specific CTLs formed cytotoxic immune synapses with and directly injured axons expressing antigen-loaded MHC I molecules.
Introduction
Multiple sclerosis (MS) is the leading cause of non-traumatic neurological disability for young people in Western countries (Conway and Cohen, 2010) . Central nervous system (CNS) axon injury and loss are histopathological correlates of irreversible neurological deficits in MS patients (Dutta and Trapp, 2007; Ferguson et al., 1997; Tallantyre et al., 2010) . Axon injury is most prominent within active, inflammatory demyelinated MS lesions enriched in macrophages and cytotoxic CD8 + T lymphocytes (CTLs) of an effector, memory phenotype (Bjartmar and Trapp, 2001; Booss et al., 1983; Hauser et al., 1986; Kornek et al., 2000; Peterson et al., 2001; Trapp et al., 1998; Traugott et al., 1983) . Acute axon injury and loss of neurologic function independently correlate with intra-lesion CTL burden and CTL populations within the lesions, blood and cerebrospinal fluid (CSF) of MS patients are clonally expanded (Babbe et al., 2000; Bitsch et al., 2000; Frischer et al., 2009; Jacobsen et al., 2002; Junker et al., 2007; Kuhlmann et al., 2002; Skulina et al., 2004) . Demyelinated axons within active, inflammatory lesions express major histocompatibility complex class I (MHC I) molecules and are therefore potential CTL targets (Hoftberger et al., 2004; Liblau et al., 2013; Neumann et al., 2002) . The cytotoxic mechanisms used by CTLs include Fas-L induction of target cell apoptosis, cytokine-mediated toxicity and target cell killing induced by the perforin-granzyme cascade (Goverman, 2009) . CSF levels of granzyme B (GzB) correlate with relapse rate in a sub-population of MS patients (Malmestrom et al., 2008) and animal models of MS link CTL effector functions to axon loss and development of neurological deficits. In the Theiler's murine encephalomyelitis model, genetic deletion of perforin (PFP) or the disruption of MHC I surface expression by genetic deletion of β2-microglobulin result in protection of axons and preservation of neurologic function, despite extensive CNS demyelination (Deb et al., 2009 (Deb et al., , 2010 Howe et al., 2007; Rivera-Quinones et al., 1998) .
The mechanism(s) of antigen-specific CTL-mediated axon injury is currently unknown. Mature axons are typically, although incorrectly, considered incapable of expressing surface levels of functional, antigen-presenting MHC I molecules sufficient to trigger CTL recognition and concomitant injury (Joly and Oldstone, 1992; Medana et al., 2000 Medana et al., , 2001 Neumann et al., 1995 Neumann et al., , 1997 Rensing-Ehl et al., 1996) . Accordingly, most hypotheses examining CTL function in the context of Neurobiology of Disease 59 (2013) 194-205 
